Nionyx Bio is advancing kidney-targeted AAV gene therapies using next-generation capsids engineered for renal delivery and validated in human kidney tissues. Our approach is designed to improve specificity, lower dosing, and increase translational confidence, with initial programs in Alport syndrome and APOL1-mediated kidney disease and a platform enabling expansion across additional renal indications.